08 Oct 2020 Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.
21 Sep 2020 24th Sept 2020 – Oblique Therapeutics is delighted to be invited to speak at “Biopharma Conclave 2020”
14 Sep 2020 Oblique Therapeutics is honored to participate as speaker to the 2nd Edition RAS- Targeted Drug Development Congress 15th September 2020
29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
11 Jun 2020 Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
